- Home
- ICON vs GNPX Comparison
ICON vs GNPX Comparison
Compare ICON & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- GNPX
- Stock Information
- Founded
- ICON 2023
- GNPX 2009
- Country
- ICON Greece
- GNPX United States
- Employees
- ICON N/A
- GNPX N/A
- Industry
- ICON
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- GNPX Health Care
- Exchange
- ICON Nasdaq
- GNPX Nasdaq
- Market Cap
- ICON 4.7M
- GNPX 5.5M
- IPO Year
- ICON 2024
- GNPX 2018
- Fundamental
- Price
- ICON $2.21
- GNPX $0.25
- Analyst Decision
- ICON Strong Buy
- GNPX
- Analyst Count
- ICON 1
- GNPX 0
- Target Price
- ICON $4.50
- GNPX N/A
- AVG Volume (30 Days)
- ICON 37.5K
- GNPX 24.1M
- Earning Date
- ICON 09-10-2025
- GNPX 11-12-2025
- Dividend Yield
- ICON 426.34%
- GNPX N/A
- EPS Growth
- ICON N/A
- GNPX N/A
- EPS
- ICON N/A
- GNPX N/A
- Revenue
- ICON $6,137,000.00
- GNPX N/A
- Revenue This Year
- ICON $94.05
- GNPX N/A
- Revenue Next Year
- ICON $18.81
- GNPX N/A
- P/E Ratio
- ICON N/A
- GNPX N/A
- Revenue Growth
- ICON 25.60
- GNPX N/A
- 52 Week Low
- ICON $1.60
- GNPX $0.14
- 52 Week High
- ICON $130.80
- GNPX $3.97
- Technical
- Relative Strength Index (RSI)
- ICON 51.92
- GNPX 55.04
- Support Level
- ICON $1.87
- GNPX $0.22
- Resistance Level
- ICON $2.37
- GNPX $0.32
- Average True Range (ATR)
- ICON 0.11
- GNPX 0.05
- MACD
- ICON 0.04
- GNPX 0.01
- Stochastic Oscillator
- ICON 67.00
- GNPX 39.73
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.